Gene therapy is expected to cure a genetic skin disease causing blisters

The researchers conducted a series of research using recombinant dog proteins and concluded that gene therapy is expected to cure a genetic skin disease, and this skin disease can cause blisters. In an early clinical trial, researchers at Stanford University School of Medicine tested this therapy on four patients with dystrophic dystrophic epidermolysis bullosa.

Researchers said that people with recessive dystrophic bullous epidermolysis can't synthesize proteins that link the upper and lower layers of the skin together. Even with small frictions, these cortices slide and produce blisters. In the worst case, the patient would die in infancy.

In this study, researchers transplants patients' own hereditary correct skin graft to the wound caused by skin disease. Transplanted skin can promote wound healing, and it is well-tolerated.

"Our Phase I clinical trials show that this therapy is safe and we are fortunate to see some good clinical results," said Dr. Jean Tang, associate professor of dermatology. In some cases, some wounds that had not healed for 5 years have been successfully treated using gene therapy. For patients, it means a substantial increase in quality of life.

The next step is to evaluate the effect of this therapy on patients older than 13 years. If it can treat children, then it can be used to prevent serious chronic wounds and scar formation. However, more trials are needed to make this therapy a widely-accepted clinical routine therapy. The study has been published in the journal American Medical Association on November 1. Flarebio offers good-quality recombinant proteins like recombinant TLR2 at competitive prices.